New 'Living Drug' trial aims to stop aggressive childhood cancers from returning
NCT ID NCT07476027
Summary
This early-phase study is testing a new type of CAR-T cell therapy for children and teenagers with high-risk T-cell leukemia or lymphoma. The goal is to see if collecting a patient's own immune cells, modifying them to target cancer, and reinfusing them can safely prevent the cancer from coming back after initial chemotherapy. The study will enroll up to 10 young patients who are in their first remission but are at very high risk of relapse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.